This is a working overview of thymus extract, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-28. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
== Applications == Lithium, sodium, and potassium have many useful applications, while rubidium and caesium are very notable in academic contexts but do not have many applications yet. Lithium is the key ingredient for a range of lithium-based batteries, and lithium oxide can help process silica. Lithium stearate is a thickener and can be used to make lubricating greases; it is produced from lithium hydroxide, which is also used to absorb carbon dioxide in space capsules and submarines. Lithium chloride is used as a brazing alloy for aluminium parts. In medicine, some lithium salts are used as mood-stabilising pharmaceuticals. Metallic lithium is used in alloys with magnesium and aluminium to give very tough and light alloys. Sodium compounds have many applications, the most well-known being sodium chloride as table salt. Sodium salts of fatty acids are used as soap. Pure sodium metal also has many applications, including use in sodium-vapour lamps, which produce very efficient light compared to other types of lighting, and can help smooth the surface of other metals. Being a strong reducing agent, it is often used to reduce many other metals, such as titanium and zirconium, from their chlorides. Furthermore, it is very useful as a heat-exchange liquid in fast breeder nuclear reactors due to its low melting point, viscosity, and cross-section towards neutron absorption. Sodium-ion batteries may provide cheaper alternatives to their equivalent lithium-based cells.
Absinthe has been frequently described in modern times as being hallucinogenic, a claim refuted by modern science. The belief that absinthe induces hallucinogenic effects is rooted, at least partly, in the findings of 19th-century French psychiatrist Valentin Magnan, who carried out ten years of experiments with wormwood oil. In the course of this research, he studied 250 cases of alcoholism and concluded that those who abused absinthe were worse off than those who abused other alcoholic drinks, experiencing rapid-onset hallucinations. Such accounts by opponents of absinthe (like Magnan) were cheerfully embraced by famous absinthe drinkers, many of whom were bohemian artists or writers. Two famous artists who helped popularise the notion that absinthe had powerful psychoactive properties were Toulouse-Lautrec and Vincent van Gogh. In one of the best-known written accounts of absinthe drinking, an inebriated Oscar Wilde described a phantom sensation of having tulips brush against his legs after leaving a bar at closing time. Notions of absinthe's alleged hallucinogenic properties were again fuelled in the 1970s when a scientific paper suggested that thujone's structural similarity to tetrahydrocannabinol (THC), the active chemical in cannabis, presented the possibility of THC receptor affinity. Counterevidence to this was published in 1999. The debate over whether absinthe produces effects on the human mind in addition to those of alcohol has not been resolved conclusively. The effects of absinthe have been described by some as mind-opening.
The English word saffron is a borrowing from French, first found in a Middle English text written around 1200 as saffran. It derives from the 12th-century Old French term safran, which comes from the Medieval Latin word safranum, and from the Persian زعفران zafarān. It originated from the older زر پران zarparān, meaning 'gold-strung' in reference to the flower's golden filaments or the rich golden hue it imparts as a spice.
Sources: en.wikipedia.org
Analysts have long believed that the firm's corporate governance must determine how to contend with higher materials prices and enhanced competition from lower-priced fast-food chains, including McDonald's and Dunkin' Donuts. In October 2015, Starbucks hired its first chief technology officer, Gerri Martin-Flickinger, to lead its technology team. Starbucks maintains control of production processes by communicating with farmers to secure beans, roasting its own beans, and managing distribution to all retail locations. Additionally, Starbucks's Coffee and Farmer Equity Practices require suppliers to inform Starbucks what portion of wholesale prices paid reaches farmers. Shortly after becoming CEO, Niccol announced a new 'Back to Starbucks' strategy to win back customers. The plan including simplifying the menu and reversing rules for its cafes in North America that had allowed people to use their facilities even if they had not bought anything. On December 19, 2025, Starbucks announced Amazon's Anand Varadarajan as new chief technology officer, effective January 19, 2026.
== Synthesis == PreproGRP begins with signal peptidase cleavage to generate the pro-gastrin-releasing-peptide (proGRP), which is then processed by proteolytic cleavages, to form smaller GRP peptides. These smaller peptides are released by the post-ganglionic fibers of the vagus nerve, which innervate the G cells of the stomach and stimulate them to release gastrin. GRP regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation.
== Side effects == Oclacitinib lacks the side effects that most JAK inhibitors have in humans; instead, side effects are infrequent, mild, and mostly self-limiting. The most common side effects are gastrointestinal problems (vomiting, diarrhea, and appetite loss) and lethargy. The GI problems can sometimes be alleviated by giving oclacitinib with food. New cutaneous or subcutaneous lumps, such as papillomas, can appear, and dogs face an increased susceptibility to infections such as demodicosis. There is a transient decrease in neutrophils, eosinophils, and monocytes, as well as in serum globulin, while cholesterol and lipase levels increase. The decrease in white blood cells lasts only around 14 days. None of the increases or decreases are clinically significant (i.e. none push their corresponding values out of normal ranges). Less common side effects of oclacitinib include bloody diarrhea; pneumonia; infections of the skin, ear, and/or urinary tract; and histiocytomas (benign tumors). Increases in appetite, aggression, and thirst have also been reported.
Sources: en.wikipedia.org
=== Environmental and food safety tests === Paper-based microfluidic devices have several applications outside of the medical field. For example, paper-based biosensors have been used extensively in environmental monitoring. Two recent devices were developed for the detection of Salmonella and E. coli. The latter device was specifically used to detect E. coli in seven field water samples from Tucson, Arizona. Antibody-conjugated polystyrene particles were loaded in the middle of the microfluidic channel, after the sample inlet. Immunoagglutination occurs when samples containing Salmonella or E. coli, respectively, come into contact with these particles. The amount of immunoagglutination can be correlated with increased Mie scattering of light, which was detected with a specialized smartphone application under ambient light. Paper-based microfluidics has also been used to detect pesticides in food products, such as apple juice and milk. A recent design used piezoelectric inkjet printing to imprint paper with the enzyme acetylcholinesterase (AChE) and the substrate indophenyl acetate (IPA), and this paper-based microfluidic device was used to detect organophosphate pesticides (AChE inhibitors) via a decrease in blue-purple color. This device is distinguished by its use of bioactive paper instead of compartments with pre-stored reagents, and it was demonstrated to have good long-term stability, making it ideal for field use.
== Personal life == While he was in Uppsala Williams met Jelly Klara Büchli, a Dutch student from Groningen. They married in 1952 and then lived in Oxford. Jelly read English language and literature at St Hilda's College, Oxford between 1952 and 1955, but the birth of their first son, Timothy Ivor, interrupted her final exams. A second son, John M, was born in 1957. In 1981 Jelly published A Dutch Reader. Bob Williams died in the John Radcliffe Hospital on 21 March 2015.
=== Female genital mutilation === The most prevalent form of non-consensual genital alteration is that of female genital mutilation. This mostly involves the partial or complete removal of the vulva. Female genital mutilation is carried out in thirty countries in Africa and Asia with more than 200 million girls being affected, and some women (as of 2018). Nearly all of the procedures are carried out on young girls. The practices are also carried out globally among migrants from these areas. Female genital mutilation is claimed to be mostly carried out for cultural traditional reasons. According to the research conducted under In the Name of Tradition, FGM/C is more common in Sunni countries and less common in Shia societies. FGM/C can have harmful effects on their physical and mental health. Various official and unofficial research reports also confirm these complications. In its various reports, the World Health Organization has considered FGM/C as an action that endangers women's health in various ways. This organization stated in a report published in January 2023 that FGM/C has no health benefits, and it harms girls and women in many ways. It involves removing and damaging healthy and normal female genital tissue, and it interferes with the natural functions of girls' and women's bodies. Although all forms of FGM/C are associated with increased risk of health complications, the risk is greater with more severe forms of FGM/C.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.